☰

Kira Gritsman - Publications

Affiliations: 
2000 New York University, New York, NY, United States 
Tree Info Grants Similar researchers PubMed Report error

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Gritsman K. FLT3-ITD gets by with a little help from PRMT1. Blood. 134: 498-500. PMID 31395582 DOI: 10.1182/Blood.2019001876  0.318
2019 Gurska LM, Ames K, Gritsman K. Signaling Pathways in Leukemic Stem Cells. Advances in Experimental Medicine and Biology. 1143: 1-39. PMID 31338813 DOI: 10.1007/978-981-13-7342-8_1  0.384
2019 Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe RO, Ames K, Ostrodka L, Haque T, Kaur I, Mills TS, Agarwal A, Pietras EM, Zhao JJ, Roberts TM, Gritsman K. PI3 kinase alpha and delta promote hematopoietic stem cell activation. Jci Insight. 5. PMID 31120863 DOI: 10.1172/Jci.Insight.125832  0.408
2018 Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, ... ... Gritsman K, et al. North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. PMID 30104217 DOI: 10.1182/Blood-2018-01-824607  0.347
2018 Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debré I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E, Verma A, Gritsman K, Steidl U. IL1RAP potentiates multiple oncogenic signaling pathways in AML. The Journal of Experimental Medicine. PMID 29773641 DOI: 10.1084/Jem.20180147  0.393
2018 Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe R, Ames K, Ostrodka L, Haque T, Kaur I, Agarwal A, Zhao J, Roberts T, Gritsman K. PI3Kinase Alpha and Delta Promote Hematopoietic Stem Activation Under Stress Blood. 132: 329-329. DOI: 10.1182/Blood-2018-99-114891  0.427
2017 Hemmati S, Haque T, Gritsman K. Inflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells. Frontiers in Oncology. 7: 265. PMID 29181334 DOI: 10.3389/Fonc.2017.00265  0.378
2017 Bhagat T, Chen S, Bartenstein M, Barlowe TS, von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, ... ... Gritsman K, et al. Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome. Cancer Research. PMID 28684528 DOI: 10.1158/0008-5472.Can-17-0282  0.361
2017 Stanley RF, Piszczatowski RT, Bartholdy B, Mitchell K, McKimpson WM, Narayanagari S, Walter D, Todorova TI, Hirsch C, Makishima H, Will B, McMahon C, Gritsman K, Maciejewski JP, Kitsis RN, et al. A myeloid tumor suppressor role for NOL3. The Journal of Experimental Medicine. PMID 28232469 DOI: 10.1084/Jem.20162089  0.379
2016 Akula MK, Shi M, Jiang Z, Foster CE, Miao D, Li AS, Zhang X, Gavin RM, Forde SD, Germain G, Carpenter S, Rosadini CV, Gritsman K, Chae JJ, Hampton R, et al. Control of the innate immune response by the mevalonate pathway. Nature Immunology. PMID 27270400 DOI: 10.1038/Ni.3487  0.312
2016 Gritsman K, Hasserjian RP, Sinclair T, Weinstock DM, Will B, Steidl U, Ballen KK, Fathi AT, Verma A, Juric D, Amrein PC. Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109 Blood. 128: 2749-2749. DOI: 10.1182/Blood.V128.22.2749.2749  0.38
2015 Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ. A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nature Communications. 6: 8501. PMID 26442967 DOI: 10.1038/Ncomms9501  0.403
2015 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U. PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood. PMID 26170031 DOI: 10.1182/Blood-2014-12-618801  0.365
2015 Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, ... Gritsman K, et al. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. Nature Medicine. 21: 71-5. PMID 25485910 DOI: 10.1038/Nm.3751  0.39
2015 Gritsman K, Kaur I, Sinclair T. The Class IA PI3 Kinase Isoforms Have Distinct but Overlapping Roles in Adult Hematopoiesis Blood. 126: 3587-3587. DOI: 10.1182/Blood.V126.23.3587.3587  0.393
2014 Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, Paktinat M, Okabe RO, Roberts TM, Zhao JJ. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α. The Journal of Clinical Investigation. 124: 1794-809. PMID 24569456 DOI: 10.1172/Jci69927  0.358
2014 Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu S, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, ... Gritsman K, et al. GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition Blood. 124: 3567-3567. DOI: 10.1182/Blood.V124.21.3567.3567  0.449
2014 Yuzugullu H, Baitsch L, Steiner A, Clayton LK, Gritsman K, Zhao JJ. Abstract 4775: PI3K-p110β is required for leukemic transformation and HSC depletion in the absence of Pten Cancer Research. 74: 4775-4775. DOI: 10.1158/1538-7445.Am2014-4775  0.421
2012 Gritsman K, Clayton L, Gilliland DG, Roberts TM, Zhao J. The p110alpha and p110delta Isoforms of PI3 Kinase Are Dispensable for Hematopoietic Stem Cell Self-Renewal but Have Redundant Roles in B Cell Differentiation. Blood. 120: 2322-2322. DOI: 10.1182/Blood.V120.21.2322.2322  0.401
2010 Kharas MG, Gritsman K. Akt: a double-edged sword for hematopoietic stem cells. Cell Cycle (Georgetown, Tex.). 9: 1223-4. PMID 20234178 DOI: 10.4161/Cc.9.7.11362  0.367
2010 Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, Gilliland DG, Gritsman K. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood. 115: 1406-15. PMID 20008787 DOI: 10.1182/Blood-2009-06-229443  0.429
2000 Gritsman K, Talbot WS, Schier AF. Nodal signaling patterns the organizer. Development (Cambridge, England). 127: 921-32. PMID 10662632  0.537
1999 Yan YT, Gritsman K, Ding J, Burdine RD, Corrales JD, Price SM, Talbot WS, Schier AF, Shen MM. Conserved requirement for EGF-CFC genes in vertebrate left-right axis formation. Genes & Development. 13: 2527-37. PMID 10521397 DOI: 10.1101/Gad.13.19.2527  0.603
1999 Meno C, Gritsman K, Ohishi S, Ohfuji Y, Heckscher E, Mochida K, Shimono A, Kondoh H, Talbot WS, Robertson EJ, Schier AF, Hamada H. Mouse Lefty2 and zebrafish antivin are feedback inhibitors of nodal signaling during vertebrate gastrulation. Molecular Cell. 4: 287-98. PMID 10518210 DOI: 10.1016/S1097-2765(00)80331-7  0.575
1999 Gritsman K, Zhang J, Cheng S, Heckscher E, Talbot WS, Schier AF. The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell. 97: 121-32. PMID 10199408 DOI: 10.1016/S0092-8674(00)80720-5  0.629
Show low-probability matches.